Next-Gen Oncology Drugs Set New Standards in Cancer TreatmentThe Global Cancer/Oncology Drugs Market is valued at USD 183.4 ...

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in ...

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening diseaseNORWICH, England & ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

Encouraging anti-tumour activity seen across all dose levels and in various tumour indicationsClinical benefit rate of 80% for 10 patients with HER2+ oesophageal cancer who had received prior therapy ...

Human Microbiome Market OverviewThe human microbiome market is witnessing exceptional momentum and is projected to grow at an impressive CAGR of 31% over the forecast period.Key Request a free sample ...

Ad hoc announcement pursuant to Art. 53 LR Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent EP4615820 – “Crystalline Forms of Evenamide” is ...

A Comprehensive OverviewThe global Peptide Cancer Vaccine Market is valued at USD 1.2 Billion in 2025 and is projected to reach a value of USD 15.72 Billion by 2035 at a CAGR (Compound Annual Growth ...

Market OverviewThe global ostomy devices market is projected to grow at a healthy rate of 4–5% and is expected to reach approximately USD 3.2 billion by 2026. This steady expansion is driven by rising ...

LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ Unique mechanism of action with potential to slow or stop the progression of HD Cambridge, ...

The global medical image management market is projected to grow at a rate of 7-8% by 2027. This growth is primarily driven by the increasing volume of imaging procedures, rapid advancements in ...

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteersPhase 2 trial will assess ...